Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Inverkan av regelbunden konsumtion av ägg och näringsämnen berikade ägg på eksemtillståndet hos individer i Singapore

10 november 2026 uppdaterad av: Jung Eun Kim, National University of Singapore

Inverkan av regelbunden konsumtion av ägg och näringsämnen berikade ägg på eksemtillståndet i Singapore individer med eksem

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

Studieöversikt

Detaljerad beskrivning

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Studietyp

Interventionell

Inskrivning (Faktisk)

43

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Singapore
      • Singapore, Singapore, Singapore, 117550
        • Department of Food Science and Techonology, Block S13

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

21 år till 59 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. English-literate and able to give informed consent in English
  2. Male and female participants, aged between 21 and 59 inclusive
  3. Healthy individuals with no underlying condition or on regular medication
  4. BMI between 18.5-25 kg/m2
  5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

  1. Significant change in body weight (3 kg or more) in the past 3 months
  2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
  3. Known food allergy to eggs
  4. Taking dietary supplements which may impact the study results
  5. Having gastrointestinal disorders not suitable for the study
  6. Current smokers
  7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
  8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
  9. Pregnant or lactating women, or planning to conceive in the next 6 months
  10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
  11. Hierarchical link (professional and familial ties) with the research team members
  12. Participating in another clinical study
  13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
  14. Low-quality macular pigment optical density results were determined during the screening visit.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Regular egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 regular egg/day for 12 weeks.

Consumption of regular egg with habitual diet

Experimentell: Nutrient-fortified egg with habitual diet

Each subject will be provide one-on-one dietary counselling and written instructions for each subject will be provided by a research dietitian and trained research staff.Subjects will also be provided with 2 nutrient-fortified egg/day for 12 weeks.

Consumption of nutrient-fortified eggs with habitual diet

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Skin questionnaires - SCORing Atopic Dermatitis (SCORAD) Index
Tidsram: Week 0, week 3, week 6, week 9, week 12

SCORing Atopic Dermatitis (SCORAD) Index is a clinical tool used to assess the severity of atopic dermatitis (AD), also known as eczema. This index can estimate participants' body surface area affected by burns (extent - A: percentage of body surface area affected), Intensity (B: clinical signs are assessed and scored on a scale from 0 (absent) to 3 (severe)), Subjective Symptoms (C: itch, sleep disturbance are evaluated based on the participants' report over the past three days, each scored on a scale from 0 (no symptom) to 10(severe symptom)).

The SCORAD index is calculated using the following formula:

SCORAD=A/5+7B/2+C

Interpretation Mild atopic dermatitis: SCORAD < 25 Moderate atopic dermatitis: SCORAD 25-50 Severe atopic dermatitis: SCORAD > 50

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Eczema Area and Severity Index (EASI) scoring system
Tidsram: Week 0, week 3, week 6, week 9, week 12

EASI evaluates the extent and severity of eczema in four body regions: the head and neck, the trunk, the upper limbs, and the lower limbs.

The EASI score ranges from 0 to 72, with higher scores indicating more severe eczema:

0: No eczema 1-7: Mild eczema 8-21: Moderate eczema 22-50: Severe eczema 51-72: Very severe eczema

Week 0, week 3, week 6, week 9, week 12
Skin questionnaires - Dermatology life quality index (DLQI)
Tidsram: Week 0, week 3, week 6, week 9, week 12

DLQI is a dermatology-specific instrument used to measure the impact of skin diseases on patients' quality of life. Which assessed disease impact, monitor treatment effectiveness, guide clinical decision-making.

Interpretation of Scores:

0-1: No effect on patient's life 2-5: Small effect on patient's life 6-10: Moderate effect on patient's life 11-20: Very large effect on patient's life 21-30: Extremely large effect on patient's life

Week 0, week 3, week 6, week 9, week 12
Skin measurement - eczema related
Tidsram: Week 0, week 3, week 6, week 9, week 12

Skin hydration - units arbitrary Corneometer®. Transepidermal water loss - units gram/hour. Sebum level - unit µg/cm2. Skin pH level - skin pH meter. Skin tape stripping: stratum corneum components assessed by immune dot blots

Week 0, week 3, week 6, week 9, week 12
Skin carotenoids status
Tidsram: Week 0, week 3, week 6, week 9, week 12

Skin carotenoids concentration can be measured by Resonance Raman Spectroscopy, unit is skin carotenoid score, higher score means optimal, lower score means poor condition of skin carotenoids.

Week 0, week 3, week 6, week 9, week 12
Blood carotenoids levels
Tidsram: Week 0, week 6, week 12

Blood carotenoids levels can be measured by High-Performance Liquid Chromatography, unit is μmol/L.

Week 0, week 6, week 12

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Eye health - Macular Pigment Optical Density
Tidsram: Week 0, week 3, week 6, week 9, week 12

A measurement of macular pigment of the eye using a heterochromatic flicker photometry device. The measurements are in arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Eye health - Visual acuity
Tidsram: Week 0, week 3, week 6, week 9, week 12

Participants will read out letters on a ETDRS LogMAR chart at a fixed distance where letters becomes smaller as it goes down the chart. Tests results will be recorded in number of letters read, where the more letters the better the outcome.

Week 0, week 3, week 6, week 9, week 12
Eye health - Photostress recovery time
Tidsram: Week 0, week 3, week 6, week 9, week 12

An ophthalmoscope will be used to shine a light into the participants eye for 10 seconds, and participants will be required to read letters off a chart the moment their vision returns to normal. The faster the recovery time, the better the outcome. Units will be in seconds

Week 0, week 3, week 6, week 9, week 12
Visual function questionnaire 25
Tidsram: Week 0, week 3, week 6, week 9, week 12

A questionnaire to for participants to self-evaluate their perception of their current eye health based on general vision, ocular pain, near activities, distance activities, vision specific functions, driving, color vision and peripheral vision. The best possible score is 100 and worst possible score is 0.

Week 0, week 3, week 6, week 9, week 12
Concentration of tumour necrosis factor-α
Tidsram: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Tumor necrosis factor-α results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of interleukin-6
Tidsram: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Interleukin-6 results will be presented in ng/L according to the commercially available enzyme-linked immunosorbent assay kits.

Week 0, week 6, week 12
Concentration of high-sensitivity C-reactive protein
Tidsram: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. High-sensitivity C-reactive protein results will be obtained and presented in mg/L by commercial lab testing.

Week 0, week 6, week 12
Concentration of fasting blood glucose
Tidsram: Week 0, week 6, week 12

Fasting blood glucose will be measured using commercial lab testing using participants' blood, units will be in mmol/L.

Week 0, week 6, week 12
Concentration of malondialdehyde
Tidsram: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of malondialdehyde using commercially available enzyme-linked immunosorbent assay kits. Units for malondialdehyde will be in ng/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of 8-isoprostaglandin-F2α
Tidsram: Week 0, week 6, week 12

The blood obtained from the participants will be processed for storage. Analyses of 8-isoprostaglandin-F2α using commercially available enzyme-linked immunosorbent assay kits. Units for 8-isoprostaglandin-F2α will be in µmol/L according to assay kit instructions.

Week 0, week 6, week 12
Concentration of insulin
Tidsram: Week 0, week 6, week 12

Fasting blood insulin will be measured using commercial lab testing using participants' blood, units in μU/L.

Week 0, week 6, week 12
Percentage of glycated hemoglobin
Tidsram: Week 0, week 6, week 12

Glycated hemoglobin will be measured using commercial lab testing from participant's blood, units in percent.

Week 0, week 6, week 12
Skin advanced glycation end products levels
Tidsram: Week 0, week 3, week 6, week 9, week 12

Measurement of skin advanced glycation end products level using a skin autofluorescence device, where participants wlll be instructed to place their forearm over the device and a light will be shone and a reading can be captured by detecting fluorescence. The results will be presented as arbitrary units.

Week 0, week 3, week 6, week 9, week 12
Blood advanced glycation end products levels
Tidsram: Week 0, week 3, week 6, week 9, week 12

Participants will have their blood drawn by medical professionals at the Occupational Health Clinic. The blood will be processed and stored. Measurements will be done using ultra-performance liquid chromatography coupled with mass spectrometry techniques to determine the levels of advanced glycation end products. Units will be in μg/mL.

Week 0, week 3, week 6, week 9, week 12

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Dietary assessment
Tidsram: Week 0, week 3, week 6, week 9, week 12

3-day food record will be used to assess participants' dietary intake for two weekdays and one weekend day before each clinical visit.

Week 0, week 3, week 6, week 9, week 12
Measurement of height
Tidsram: Week 0, week 3, week 6, week 9, week 12

Height will be measured using height-weight scale and units will be in cm.

Week 0, week 3, week 6, week 9, week 12
Measurement of blood pressure
Tidsram: Week 0, week 3, week 6, week 9, week 12

A blood pressure monitoring device available commercially will be used be to measure their systolic and diastolic blood pressure. Unit is mmHg.

Week 0, week 3, week 6, week 9, week 12
Measurement of weight
Tidsram: Week 0, week 3, week 6, week 9, week 12

Weight will be measured using height-weight scale and units will be in kg.

Week 0, week 3, week 6, week 9, week 12
Measurement of waist circumference
Tidsram: Week 0, week 3, week 6, week 9, week 12

Waist circumference will be measured using a measuring tape by a trained personnel, units in cm.

Week 0, week 3, week 6, week 9, week 12

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Jung Eun Kim, PhD, RD, National University of Singapore

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

17 juli 2024

Primärt slutförande (Faktisk)

27 oktober 2025

Avslutad studie (Faktisk)

1 december 2025

Studieregistreringsdatum

Först inskickad

7 april 2024

Först inskickad som uppfyllde QC-kriterierna

10 juni 2024

Första postat (Faktisk)

12 juni 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

16 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

The link between participants' information data and the code will be kept confidential by the NUS research team or a trusted third party. Research data and results will only be collated in its coded format. All research data collected will be retained for a minimum of 10 years following the NUS Research Data Management Policy.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera